Johnson & Johnson (NYSE:JNJ) on Tuesday shared topline results from the Phase 2b JASMINE study of nipocalimab in lupus patients.

The systemic lupus erythematosus (SLE) is a chronic autoimmune disease where the body's immune system attacks healthy tissues and organs, causing inflammation in various parts of the body, including joints, skin, kidneys, and the brain.

Chronic symptoms of SLE include severe fatigue, joint pain and swelling, and rashes, including a hallmark butterfly-shaped facial rash.

The 228-subject study met the primary endpoint (percentage of patients achieving Systemic Lupus Erythematosus Responder Index, a composite response at Week 24 with statistical significance compared with placebo), and key secondary and exploratory endpoints, including those indicating the potential of nipocalimab for steroid sparing.

Nipocalimab had ...